Literature DB >> 3613404

An evaluation of the development of experimental membranous nephropathy.

F B Gabbai, L C Gushwa, C B Wilson, R C Blantz.   

Abstract

Heymann nephritis is a rat model of glomerulonephritis with morphologic manifestations of human membranous nephropathy. This model is generated by immunizing rats with Fx1A antigen. Passive Heymann's nephritis (PHN) can be produced by the administration of anti-Fx1A antibody (anti-Fx1A Ab) (with abnormal proteinuria appearing in 5 days). Studies were designed to examine the evolution of temporal changes in protein excretion, the glomerular ultrafiltration coefficient (LpA) and morphology of glomerular capillary three and five days after induction of PHN. Glomerular hemodynamic evaluation by micropuncture in euvolemic rats with PHN revealed normal values for nephron filtration rate (SNGFR), LpA and the glomerular hydrostatic pressure gradient (delta P) at day three, but by day five the whole kidney GFR and SNGFR were decreased, delta P increased and LpA significantly reduced. Glomerular binding of anti-Fx1A Ab increased from 38 micrograms/7.6 X 10(4) glomeruli on day three to 52 micrograms on day five. Immune complex deposits evaluated by immunofluorescence and electron microscopy appeared larger and were better defined on day five than on day three. Epithelial foot process fusion was more extensive on day five than day three. The onset of increased proteinuria correlated temporally with a reduction in LpA on day five, which in turn correlated with increased antibody binding, immune deposit accumulation and fusion of epithelial cell foot processes.

Entities:  

Mesh:

Year:  1987        PMID: 3613404     DOI: 10.1038/ki.1987.140

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats.

Authors:  P J Baker; R F Ochi; M Schulze; R J Johnson; C Campbell; W G Couser
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

2.  Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients.

Authors:  E Menegatti; D Roccatello; K Fadden; G Piccoli; G De Rosa; L M Sena; A Rifai
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Complement C5b-9 induces receptor tyrosine kinase transactivation in glomerular epithelial cells.

Authors:  A V Cybulsky; T Takano; J Papillon; A J McTavish
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

4.  Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies.

Authors:  C J Raats; J van den Born; M A Bakker; B Oppers-Walgreen; B J Pisa; H B Dijkman; K J Assmann; J H Berden
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

5.  Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells : role of cyclooxygenase-1 and -2.

Authors:  T Takano; A V Cybulsky
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 6.  Glomerular function reserve and sodium sensitivity.

Authors:  Genjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2005-06       Impact factor: 2.801

7.  Para-capillary electron-dense deposits reduce glomerular filtration in patients with primary glomerular diseases.

Authors:  Sachiko Fukase; Junichiro J Kazama; Honami Mori; Seitaro Iguchi; Tetsuro Takeda; Mitsuhiro Ueno; Shinichi Nishi; Ichiei Narita; Fumitake Gejyo
Journal:  Clin Exp Nephrol       Date:  2006-03       Impact factor: 2.801

8.  Functional effects on glomerular hemodynamics of short-term chronic cyclosporine in male rats.

Authors:  S C Thomson; B J Tucker; F Gabbai; R C Blantz
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

9.  Leukotriene D4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis.

Authors:  T Katoh; E A Lianos; M Fukunaga; K Takahashi; K F Badr
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.